Goldman Sachs Initiates Coverage On Celldex Therapeutics with Neutral Rating, Announces Price Target of $45
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has initiated coverage on Celldex Therapeutics with a Neutral rating and set a price target of $45.
September 30, 2024 | 10:39 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has initiated coverage on Celldex Therapeutics with a Neutral rating and a price target of $45, indicating a balanced view on the stock's potential.
The Neutral rating suggests that Goldman Sachs does not expect significant short-term movement in Celldex's stock price. The price target of $45 provides a benchmark for investors, but the neutral stance indicates no strong buy or sell recommendation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100